Trichuris Trichiura; Infection, Hookworm Infection, Ascaris Lumbricoides Infection
Conditions
Keywords
Trichuris trichiura, Ascaris lumbricoides, STH, Efficacy, Safety, Hookworm, Emodepside, Soil-transmitted helminths, Roundworm, Whipworm, Mebendazole
Brief summary
This study aims to assess the efficacy and safety of emodepside compared to mebendazole in adults and adolescents infected with T. trichiura, either as single infection or co-infections with hookworm and/or A. lumbricoides.
Interventions
Treatment with single dose of oral 15 mg emodepside
Treatment with single dose of oral emodepside matching placebo
DRUGMebendazole
Treatment with 100 mg mebendazole orally administered b.i.d. for 3 days
Treatment with mebendazole similar placebo orally administered b.i.d. for 3 days
Sponsors
Public Health Laboratory Ivo de Carneri
Bayer
Silicon Valley Community Foundation
Swiss Tropical & Public Health Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Sponsor staff, Site staff,
Eligibility
Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or non-pregnant (confirmed by a negative serum pregnancy test) and non-breastfeeding female participants aged 12 years and older. 2. T. trichiura as a single infection or co-infection with hookworm and/or A. lumbricoides, confirmed by presence of T. trichiura eggs assessed by Kato-Katz thick smears from two stool samples (infection intensity defined as number of eggs per gram of stool (EPG): (1) light (1-999 EPG), (2) moderate to heavy (≥1000 EPG). 3. A minimum infection intensity of 24 eggs per gram of stool at baseline and at least two positive slides out of the four slides assessed at baseline. 4. Written informed consent signed by the participant and/or legally authorized representative(s) according to the participant's age as established per local regulations. In addition, participant's assent is required as applicable by local laws and regulations for adolescents of 12-17 years of age. 5. Women of childbearing potential must agree to use an effective, culturally appropriate contraceptive measure from at least 28 days prior to first dosage for hormonal contraceptives only and for non-hormonal contraceptive measures from screening Visit 2 until End of Study Visit.
Exclusion criteria
1. Presence of any systemic illnesses, renal and/or hepatic impairment, any other acute or chronic health conditions or congenital disorders which, in the opinion of the Investigator, would make the participant unsuitable for participation in a clinical study or may interfere with the efficacy, safety, and/or pharmacokinetic (PK) evaluation of the study drug. 2. Any of the following: 1. Platelet \<75,000/mm3 2. Alanine Aminotransferase (ALT) or Serum Glutamic Pyruvic Transaminase (SGPT) \>3x upper limit of normal (ULN) 3. Total bilirubin \>2xULN 4. Estimated Glomerular Filtration Rate (eGFR) \<90 ml/min/1.73 m2 (adolescents) or estimated creatinine clearance (CrCl) \<90 ml/min (adults) 3. Treatment with the following anthelminthic drugs: albendazole, mebendazole, ivermectin, within 28 days before the first dose of study intervention or planned before End of Study Visit. 4. Use of sensitive CYP3A4 substrates within 14 days before the start of the first study intervention and until at least 14 days after the last administration of study intervention (detailed list of prohibited medication is provided in Section 6.5.1). 5. Treatment with metronidazole within 2 days before the first dose of study intervention or planned before 24 hours after last administration of study intervention. 6. Previous assignment to a study intervention for another study planned to be administered during the period the participant is enrolled in this study (from date of informed consent to last follow-up). 7. Known allergy/hypersensitivity to mebendazole and/or emodepside
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cured of T. trichiura infection | Test of Cure Visit at 14 to 21 days after end of treatment | Determined by negative Kato-Katz thick smears in two stool samples taken at the Test of Cure Visit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cured of A. lumbricoides infection | Test of Cure Visit at 14 to 21 days after end of treatment | Determined by negative Kato-Katz thick smears in two stool samples taken at the Test of Cure Visit. This endpoint is only applicable for the subgroup of participants co-infected with A. lumbricoides at baseline. |
| Occurrence of TEAEs | Adverse events that occur after the first dose of study intervention up to 21 days after the last dose of study intervention | Defined as any AE that occurred or worsened after the first dose of study intervention up to 21 days after the last dose of study intervention |
Other
| Measure | Time frame | Description |
|---|---|---|
| Cured of hookworm infection | Test of Cure Visit at 14 to 21 days after end of treatment | Determined by negative Kato-Katz thick smears in two stool samples taken at the Test of Cure Visit. This endpoint is only applicable for the subgroup of participants co-infected with hookworm at baseline. |
| Egg reduction of each species of STH (T. trichiura, A. lumbricoides and hookworm infection) | Test of Cure Visit at 14 to 21 days after end of treatment | Defined as logarithm of the number of eggs/g (+1) from stool samples taken at the Test of Cure Visit minus the logarithm of the number of eggs/g (+1) in stool samples taken at baseline. Egg reduction of A. lumbricoides and hookworm will only be calculated in participants co-infected with A. lumbricoides and hookworm at baseline, respectively. |
| Listing of individual plasma concentrations of emodepside | Plasma concentrations at 3, 6, 21-48 hours and 14-21 days after the end of treatment | — |
Countries
Tanzania
Outcome results
None listed